Sanofi, Hanmi sign diabetes treatment license agreement
Thursday, November 05, 2015
France's Sanofi said on Thursday that it had signed a license agreement with Korea-based Hanmi Pharmaceutical Co. Ltd. to develop a portfolio of experimental, long-acting diabetes treatments.
Hanmi will receive an upfront payment of 400 million euros ($434 million) and is eligible for up to 3.5 billion euros in development, registration and sales milestones, Sanofi said in a statement.
Sanofi will obtain an exclusive worldwide license to develop and commercialize a series of therapies.
news.yahoo.com
